Food Allergy Market Size and Trend Report including Marketed and Pipeline Drug Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030

Food allergy (FA) is defined as an adverse immunologic response to food. While any food can cause an adverse reaction, eight types of food allergens account for about 90% of all reactions: eggs, milk, peanuts, tree nuts, fish, shellfish, wheat, and soybeans.

Food-induced allergic disorders are broadly classified into immunoglobulin E (IgE)-mediated, cell-mediated (non-IgE-mediated), or both IgE- and cell-mediated mechanisms (mixed IgE- and non-IgE-mediated). IgE-mediated allergic responses are the most common type of food allergy, with rapid onset of symptoms after ingestion

For the scope of this report, the publisher will use the IgE-mediated classification and will mainly focus on that classification throughout.

The current treatment options consist of drugs taken after accidental allergen exposure, with nothing aimed to cure patients of their allergy.

Treatment options differ based on the severity of the reaction. Antihistamines are used for mild to moderate reactions and epinephrine is used for severe or anaphylaxis reactions.

The food allergy market lacks a curative agent, with the only available treatments being antihistamines or epinephrine usage for accidental exposure.

A total of 10 out of 12 therapeutic classes in development are first-in-class drugs introducing novel mechanisms of action to food allergy, including immunoglobulin E (IgE) inhibitors, desensitization immunotherapy (allergen), interleukin inhibitors, anti-inflammatory, Bruton tyrosine kinase (BTK) inhibitor, sphingosine 1-phosphate receptor agonist, lanthionine synthetase component c-like protein 2 (LANCL2) agonist, mast cell stabilizer, and glucocorticoid receptor agonist.

The greatest unmet needs within the food allergy market are more treatment options, better medications with less side effects, lack of data, limited access, and better education.

Despite having 31 pipeline agents, significant unmet needs are expected to remain, representing an opportunity for developers in the food allergy market.

The peanut allergy market is the most valuable segment within the food allergy due to sales of Palforzia and Viaskin Peanut.

Viaskin Peanut is expected to be the most profitable drug for food allergy with sales of $1.5 billion by 2030.

Scope

• Overview of FA including, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines
• Key topics covered include current treatment and pipeline therapies, trends, clinical trials, unmet needs, challenges and opportunities, and market analysis
• Analysis of the current and future market competition in FA therapeutics market

Reasons to Buy

The report will enable you to:

• Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines
• Develop business strategies by understanding the trends shaping and driving the FA therapeutics market
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the FA market in the future
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
• Track drug sales in the FA therapeutics market from 2020-2030
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships